Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04205409 · ClinicalTrials.gov registry record · Phase 2
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
A Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma and Recurrent Plasma Cell Myeloma, sponsored by University of Washington.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04205409 is a Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma and Recurrent Plasma Cell Myeloma that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 20 participants, below the 48-participant average among 43 other Recurrent Diffuse Large B-Cell Lymphoma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04205409, a Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma and Recurrent Plasma Cell Myeloma, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-06-05 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04205409
The ClinicalTrials.gov registry entry for NCT04205409 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 43 other Recurrent Diffuse Large B-Cell Lymphoma trials with a reported enrollment target (58% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Diffuse Large B-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT04205409 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT04205409 about?
NCT04205409 is a clinical study titled "Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies". This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune syste...
What is the current status of trial NCT04205409?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-06-05. Estimated completion is 2029-08-01.
What conditions does trial NCT04205409 study?
This clinical trial studies the following conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT04205409?
The interventions under investigation include: Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04205409?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04205409 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Diffuse Large B-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RECRUITING · Phase 2
-
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
RECRUITING · Phase 2
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
-
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
RECRUITING · Phase 2
-
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
RECRUITING · Phase 2
-
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Recurrent Diffuse Large B-Cell Lymphoma
All registered trials for this condition
Recurrent Plasma Cell Myeloma
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.